2,260 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Sage Rhino Capital LLC

Sage Rhino Capital LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,260 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 293,356 shares of company stock worth $29,166,240 over the last three months. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.5 %

Gilead Sciences stock opened at $115.99 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $117.16. The company has a market cap of $144.55 billion, a PE ratio of 313.49, a PEG ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business’s 50-day simple moving average is $97.87 and its two-hundred day simple moving average is $90.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.72%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Finally, Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.